Genmab Announces $14.35 Billion DARZALEX Net Sales for 2025
GMAB sits 86% above its 52-week low of $17.235.
Summary
Genmab reported worldwide net sales of its key oncology drug, DARZALEX, totaling $14.351 billion for 2025, from which it receives royalties.
Key Events · Product Development and Regulatory · GMAB
-
DARZALEX Net Sales Reported
Worldwide net sales of DARZALEX (daratumumab), including DARZALEX FASPRO, reached USD 14,351 million in 2025, as reported by Johnson & Johnson.
-
Geographic Sales Breakdown
U.S. net sales accounted for USD 8,266 million, while sales in the rest of the world totaled USD 6,085 million.
-
Royalty Revenue Stream
Genmab receives royalties on these worldwide net sales under its exclusive license agreement with Johnson & Johnson.
Analysis · GMAB · Life Sciences
This announcement provides crucial insight into the commercial performance of DARZALEX, a significant revenue driver for Genmab through its royalty agreement with Johnson & Johnson. The substantial sales figures for 2025 underscore the drug's continued market penetration and its importance to Genmab's financial outlook. Investors will use these figures to model Genmab's royalty income and assess the long-term value of its partnership.
At the time of this filing, GMAB was trading at $32.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.3B. The 52-week trading range was $17.24 to $35.43. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.